N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲,英文名:N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]
623142-96-1
N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲(N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea)
CAS: 623142-96-1
化学式: C24H24N4O5S
<"" ="xl" "">| 中文名 | N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲 |
| 英文名 | N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea |
| 别名 | 1-(4-((6,7-二甲基-4-基)氧基)-2-甲氧基苯基)-3-(1-(噻唑-2-基)乙基)脲 N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲 |
| 英文别名 | KI20227 Ki20227 CS-1094 KI 20227 KI-20227 N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea 1-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)-2-methoxyphenyl)-3-(1-(thiazol-2-yl)ethyl)urea 1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-3-[1-(1,3-thiazol-2-yl)ethyl]urea Urea, N-[4-[(6,7-diMethoxy-4-quinolinyl)oxy]-2-Methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]- |
| CAS | 623142-96-1 |
| EINECS | 200-258-5 |
| 化学式 | C24H24N4O5S |
| 分子量 | 480.54 |
| 密度 | 1.327 |
| 沸点 | 621.8±55.0 °C(Predicted) |
| 闪点 | 329.846 °C |
| 酸度系数 | 12.03±0.46(Predicted) |
| 存储条件 | Sealed in dry,Store in freezer, under -20°C |
| 外观 | 棕色粉末。 |
| 体外研究 | Ki20227 (0.1-1000 nM; 72 hours) with 100 and 1,000 nM almost suppresses M-NFS-60 cell growth and HUVEC cell growth, respectively. Ki20227 (0.1-1000 nM; 1 hour) suppresses M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner. Cell Viability Assay Cell Line: M-NFS-60 cells, HUVEC cells, human A375 melanoma cells Concentration: 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM Incubation Time: 72 hours Result: 100 and 1,000 nM almost suppressed M-NFS-60 cell growth and HUVEC cell growth, respectively. Cell Viability Assay Cell Line: RAW264.7 cell lysate Concentration: 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM Incubation Time: 1 hour Result: Suppressed M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner. |
| 体内研究 | Ki20227 (orally;10-50 mg/kg/d for 20 days) of 50 mg/kg/d of Ki20227 for 20 days markedly decreases the osteolytic lesion areas. ki20227 during global ischemia led to a significant deficit in microglial density in the CNS in mice, and CSF1R-inhibition led to a significant reduction in the neuronal density of mice. Animal Model: 4-week-old male F344/NJcl-rnu rats Dosage: 10, 20, and 50 mg/kg Administration: Orally; once per day for 20 days Result: Oral administration of 50 mg/kg/d markedly decreased the osteolytic lesion areas. |
623142-96-1 - 配置溶液浓度参考
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.081 ml | 10.405 ml | 20.809 ml |
| 5 mM | 0.416 ml | 2.081 ml | 4.162 ml |
| 10 mM | 0.208 ml | 1.04 ml | 2.081 ml |
| 5 mM | 0.042 ml | 0.208 ml | 0.416 ml |
623142-96-1 - 简介
N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲是一种有机化合物，具有以下性质和用途：性质：
- 外观为白色或类白色结晶粉末
- 可溶于有机溶剂如甲醇和二氯甲烷
用途：
制法：
- 制备N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲的方法可以通过化学合成来实现。
- 化学合成的步骤一般包括如下几个步骤：通过反应合成噻唑乙酸酯，加入氨基苯甲酸，反应生成腈化合物，然后使用亚硝酸钠加热反应得到目标产物。
安全信息：
- 在实验室使用此化合物时，应采取适当的个人防护措施，如佩戴实验手套、眼镜和实验室衣物，以避免接触和吸入。
- 在处理和储存化合物时，应遵循相关的化学安全操作规程，确保安全使用。最后更新：2024-04-09 19:05:04
